Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participant~* Age ≥ 16 years~* Patient with relapsed or refractory CD19 positive B-acute lymphoblastic leukaemia (B-ALL) who have exhausted alternative treatment options~* Estimated life expectancy ≥ 12 weeks (according to investigator's judgement)~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2~Exclusion Criteria:~* Previous treatment with gene or gene-modified cell therapy medicine products or adoptive T cell therapy~* Use of previous anti-leukemic therapy (including approved therapies and other investigational products) within 5 half-lives prior to UCART19 administration~* CD19 negative B-cell leukaemia~* Burkitt cell or mixed lineage acute leukaemia

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- UCART19 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).